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Monoclonal antibodies (moAbs) that recognize common or variable determinants of the gd T-cell receptor (TcR) were used
to assess gd T-cell distribution on biopsy specimens and/or peripheral blood leukocytes (PBL) from 30 patients suffering from
chronic cutaneous lupus erythematosus (CCLE). CD3þ /gd TcRþ T cells were evaluated in 15 biopsies from patients with
CCLE lesions, their numbers varying from 0.5 to 15.0% of all intralesional CD3þ T cells present. In all specimens from
lesional skin gd TCRþ T cells were BB3þ and/or TiyA þ , indicating predominant use of the Vg2/Vd2 phenotype. In the CCLE
lesions the intraepidermal Vg2/Vd2þ T cells were observed in close vicinity to the damaged basal keratinocyte (KC) layer, and
also randomly scattered among the densely packed inflammatory infiltrate in the dermis. In contrast to the
immunohistologic findings, no numerical increase of gd TcRþ T cells could be observed among PBL from 28 of 30 CCLE
patients. Only one CCLE patient being treated with hydroxychloroquine for two months had 15% CD3þ /gd TcRþ T cells
among the PBL. Based on the immunohistologic findings one may infer that in CCLE, a skin-restricted form of LE, Vg2/Vd2þ
T cells expand extrathymically to an as yet unknown stimulus. One may also propose that these gd T cells – based on
their cytotoxic capacity – may contribute to the epidermal damage. It remains to be determined whether the extra-
thymic expansion of Vg2/Vd2þ Tells occurs within lesional skin or in the periphery within subsequent recruitment into skin
lesions. The results obtained by fluorescence-activated cell sorter analysis favor the first possibility. J Invest Dermatol
100:84S–91S, 1993
T cells recognize foreign antigens via T-cell receptors (TcR), which are
heterodimeric, immunoglobulin-like structures, expressed on the cell
surface in context with the CD3 molecule [1]. Two types of TcR are used
by normal human T cells, ab TcR [1] and gd TcR [2]. The genes encoding
the TcR chains are composed by V, D, J, and two C regions that undergo
somatic rearrangement during ontogeny [3,4]. In contrast to ab TcR-
bearing T cells, the germline diversity of gd TcRþ T cells is limited. So
far, there are 14 Vg gene segments, divided into four subgroups, and
possibly 5–10 Vd gene segments identified in humans [4]. This limited
germline diversity suggests that TcR gd- bearing T cells recognize antigen
in the context of monomorphic rather than polymorphic antigen-
presenting molecules [4]. Alloreactive gd TcRþT cells specific for major
histo-compatibility complex (MHC) class I, class II, class I-like gene
products (Tla and Qa), as well as non-MHC-encoded CD1 antigens have
been described [5–8]. In addition, gd TcRþT cells proliferate in a non-
MHC restricted response to mycobacterial antigens [9–11], to heat-shock
proteins [12], and tetanus toxoid [13].
Whereas the ab TcR is found on 70–90% of either CD3þ /CD4þ or
CD3þ /CD8þ T cells in the peripheral blood and lymphoid tissues of
healthy human adults, only approximately 5% of T cells express the gd TcR
[14], the majority being CD3þ /CD4/CD8. A relative numerical
increase of gd TcR þ T cells was observed in lesional skin from upgrading
reactions in leprosy lesions, in lepromin tests, and in lesions from
cutaneous leishmaniasis [15]. Based on these findings a pathogenic role for
gd TCRþ T cells has been suggested for infectious and autoimmune
diseases. We therefore investigated a possible role for gd TcRþ T cells in
one of the ‘‘classical’’ autoimmune disorders, lupus erythematosus (LE).
LE is a highly variable disease and appears to consist more of a
collection of symptoms than being a disorder with a uniform clinical
pattern. Acute systemic LE (ACLE) (with only minor and transient skin
involvement) may be violent and, despite intensive immu-nosuppressive
therapy, rapidly fatal. At the opposite end of the ‘‘lupus spectrum’’ are
patients with predominant skin involvement [subacute cutaneous LE
(SCLE), chronic cutaneous LE (CCLE)] who run a benign course. However,
all clinical forms have one feature in common, i.e., photosensitivity.
Because not all individuals exposed to sunlight develop LE and/or the same
clinical expression of LE, other environmental and above all hereditary
factors are of importance. Certain LE subsets have been shown to have a
strong HLA association, e.g., SCLE patients frequently possess the HLA-B8,
DR3, DQ1-2 phenotype [16,17], whereas CCLE appears to be associated
with the haplotypes HLA-B7, B8, Cw7, DR2, DR3, and HLA-DQwl [18].
However, the development of restriction fragment length polymorphism
(RFLP) analysis allows the identification of allelic polymorphism in
addition to the phenotypic polymorphism recognized by serology and
mixed lymphocyte culture [19,20].
The aim of the present study was twofold: first, to investigate whether
the chronic cutaneous form of LE is associated with the preferential use of
T cells with a particular TcR equipment and, second, to search for
associations of CCLE with particular HLA-DR and HLA-DQ alleles (the
details of the latter investigations, however, are to be published
separately (Fischer et al, submitted).
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MATERIALS AND METHODS
Patients (Table I) Thirty patients with clinically and histologi-cally proved
CCLE lesions have been included in the study. After informed consent had
been obtained from the patients, biopsies were performed under local
anesthesia with 2% mepivacain in 14 patients. Two biopsies were obtained
from patient 16 at two different time points. For comparison, skin biopsies
from five ACLE patients and one patient with SCLE, which had been obtained
for routine immunofluorescence evaluation, were stained with the same
monoclonal antibodies (MoAbs) and with the same immuno-histochemical
method as were used for CCLE lesions. Fluorescence-activated cell sorter
(FACS) analysis from peripheral blood leukocytes (PBL) was done in 28 of 30
patients; PBLs from patients 18, 19, and 29 were analyzed at two different
time points, and from patient 16 at three different time points. MoAbs directed
against the same epitopes were used for immunohistochemistry as well as
FACS analysis. Again, PBLs from five patients with ACLE and one patient with
SCLE were evaluated for comparison.
Immunohistochemistry Biopsy specimens were divided into two parts, one
being fixed in 10% buffered formaline for paraffin embedding and routine
histopathologic examination, the other half being frozen in liquid nitrogen
and stored at 20 1C until further use.
A modified immunoperoxidase technique using the avidin-biotin-com-
plex method was employed on 3 m cryostat sections from the biopsies. Frozen
sections were placed on gelatine-coated slides, dried for 1 h, and fixed in
acetone for 10min at room temperature (RT). Sections were frozen at 20 1C
when not used immediately. After thawing and drying, sections were washed
with phosphate-buffered saline (PBS; pH 7.5) and covered with 10% sheep
serum (Dakopatts, Glostrup, Denmark) for 20min. Slides were incubated with
the primary MoAb diluted appropriately in 5% bovine serum albumin (BSA)/
PBS at 4 1C overnight (approximately 16 h). After repeated washings in PBS,
slides were successively incubated with biotinylated sheep anti-mouse Ig
(diluted 1:200 in 5% BSA/PBS; Dakopatts) for 1 h at RT. After incubation with
the avidin-biotin complex the color was developed with 3-amino-9-ethyl-
carbazole (Sigma, St. Louis, MO) in acetate buffer. The chro-mogenic reaction
was started with H2O2. Sections were counter-stained with hematoxylin
(Merck, Darmstadt, BRD), rinsed with tap water, and mounted in aquamount
(BDH Limited Poole England, supplied by Biotrade, Vienna, Austria) for
microscopic examinations.
Staining patterns and distribution of cell types with the various MoAbs
were examined by light microscopy. Cells reactive with anti-CD3 (anti-Leu4),
bF-1, and TCRd1 were counted over the entire section in consecutive high-
power fields (40 ). Numbers of TCRJl-reactive lymphocytes are given as
percentages of the total number of anti-Leu4 þ cells per section (Table I).
FACS Analysis (Single- and Double-Staining Procedures) PBLs were isolated
by Ficoll-Hypaque (Pharmacia Fine Chemicals, Piscataway, NJ) density-
gradient centrifugation and incubated for 10min at 4 1C in 10% heat-
inactivated human serum (type AB)/PBS. Cytofluorographic analysis of cell
populations was performed by means of either direct or indirect immuno-
fluorescence according to standard procedures. Briefly, 105 human PBL/
100ml were incubated with the fluorescein isothiocyanate (FITC)-labeled or
unlabeled MoAbs at dilutions of 1:10 (Becton Dickinson, San Jose, CA) or
1:20 (T Cell Sciences, Cambridge, MA) for 25min at 4 1C. After washing with
PBS-azide (895ml a.d. þ 100ml 10 PBS þ 5ml Na-azide), F(ab)2 anti-
mouse immunoglobulin G (IgG) (or IgM) was added as second-step antibody,
again, incubation was performed for 25min at 4 1C. After washing, cells were
incubated with the phycoerythrin (PE)-conjugated second MoAb for another
25min at 4 1C. Subsequently, the cells were incubated for 10min with 10%
lysing solution (Becton Dickinson, CA). Cells were washed twice and then
analyzed on a FACscan (Becton Dickinson, CA).
MoAbs (See Also Table II) In addition to a panel of phenotypic markers used
routinely, various MoAbs directed against different epitopes of TcR chains
were applied. bF-1 recognizes a common determinant of the ab TcR. MoAbs
Table I. CCLE Patients, Genetic Association, Percent







(%) Diagnosis Systemic Treatment
1 G.A. NDa 12.0b 0.7b CCLE Antibiotics, steroids
Hydroxychloroquine
2 S.H. 1B 1B 5.0 1.0 CCLE Y
3 S.G. 2 2 14.4b 1.8 CCLE Hydroxychloroquine
4 V.L. 1A 1B 10.0b 2.7 CCLE Hydroxychloroquine
5 V.B. 2 1C ND 7.8 CCLE Hydroxychloroquine
6 Y.S. 3 1B 8.0b 5.0 CCLE Hydroxychloroquine,
retinoids
7 H.E. 1B 1B 3.0 2.0 CCLE Hydroxychloroquine
8 E.G. 1B 1B 7.4b 3.2b CCLE Hydroxychloroquine
9 A.E. ND 4.2 ND CCLE Hydroxychloroquine
10 K.H. 3 1B 7.0b 2.7b CCLE Hydroxychloroquine,
antibiotics, steroids
11 K.J. 1B 1B ND 3.2b CCLE, SCLE,
Ro +
Hydroxychloroquine
12 B.T. ND 6.0 15.1b CCLE Hydroxychloroquine
13 H.A. ND 0.5 3.7 CCLE Y
14 F.H. 2 1B 15.0b 6.0 CCLE Hydroxychloroquine
15 P.J. 2 1B ND 6.1 CCLE Y
16 B.K. 1B 1B o5 2.0 CCLE Hydroxychloroquine
o5 4.0b
3.4b
17M.L. 1A 1C ND 3.5 CCLE Hydroxychloroquine
18 S.S. 1A 1B ND 1.2 CCLE Hydroxychloroquine
1.7b
19 S.J. 3 1B ND 0.3 CCLE Y
3.5b
20 S.G. 2 1C NE 1.2 CCLE Hydroxychloroquine
21 S.S. 2 1B ND 1.8 CCLE Hydroxychloroquine
22 S.E. 2 1B ND 1.9 CCLE Y
23 G.H. 1B 1B ND 0.4 CCLE Hydroxychloroquine,
retinoids, steroids
24 L.A. 1B 1C ND 2.9 CCLE Hydroxychloroquine
25 P.S. ND ND 2.3 CCLE Hydroxychloroquine
26 V.W. ND ND 3.8 CCLE Hydroxychloroquine
27 L.S. ND ND 0.6 CCLE
28 J.A. ND ND ND CCLE Y
29 VB.M 3 IB NEc 2.7 CCLE Hydroxychloroquine
5.0b
30 K.I. ND o5 ND CCLE Y
aND, not determined.
bObtained in biopsies during or after systemic treatment with hydroxy-
chloroquine.
cNE, not evaluable.
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TCRd1 and anti-TCR-g/d recognize all gd TcRþ T cells in peripheral blood as
well as in normal and diseased tissue [21,22]. BB3 is directed against Vd2, an
epitope on the disulphide-linked form of the gd TcR (44-kD chain) encoded by
the Cg1 region [23]. BB3þ T cells predominate within peripheral blood and
tonsil [24], whereas in thymus and spleen the non-disulphide linked form of
the gd TcR predominates, which is encoded by the Cg2 region [24]; this
subpopulation can be identified by the MoAbs dTCS1 [25], reactive with the
Vd1 determinant [25], and A13 [26]. BB3 þ T cells and dTCS1 þ T cells
have been shown to be two mutually exclusive T-cell populations [24]. The
MoAb Tiga recognizes the Vg9 (Vg2) gene product [27,28], which has been
shown to be combined with Vd2 in most cases.
Isotype-matched mouse MoAbs that do not react with human leukocytes
were used as controls.
RESULTS
Routine Histopathology and Immunofluorescence The clinical diagnosis
CCLE was confirmed by histopathologic examination. All biopsy speci-
mens were from lesions displaying active inflammatory as well as
scarring changes. Basal cell injury, hyperker-atosis, and follicular
plugging as well as atrophy of the nucleated portion of the epidermis
were observed, in parallel to mononuclear cell infiltrates around
appendages and blood vessels. Epidermal changes observed in the
lesional SCLE biopsy were essentially indistinguishable from those seen
in CCLE biopsies; the inflammatory mononuclear infiltrate, however, was
significantly less dense than in CCLE. The dermoepidermal junction (DEJ)
was partially obliterated by the mononuclear cell infiltrate in CCLE and
SCLE lesional skin. Deposits of immunoglobulins and complement along
the DEJ were found by direct immunofluorescence using FITC-labeled
anti-human IgG, M, A, and C3.
Histopathology of ACLE lesional skin revealed less—if at all—
epidermal changes, marked edema in the upper dermis, but only a sparse
mononuclear infiltrate.
Immunohistologic Analysis
CDla: As has been reported previously [29], a significant numerical
reduction of CDla þ dendritic epidermal cells, i.e., Langerhans cells
(LC), was observed consistently in all our CCLE specimens (Fig 1a). CDla
reactivity was seen rarely, if at all, within the dermal infiltrate (Fig 1b). In
contrast, in ACLE lesional and non-lesional skin as well as in SCLE non-
lesional skin CDlaþ LC appeared in normal distribution, shape, and
number in epidermis and dermis.
CD3 and Accessory Molecules CD4 and CD8: The majority of in-
traepidermal as well as of infiltrating dermal inflammatory cells displayed
the CD3 complex as visualized by the MoAb anti-Leu4 (Fig 2a,b),
reactive with its A-chain. The distribution pattern of the accessory
molecules CD4 and CD8 appeared to be the result of the non-random
recruitment of polyclonal T-cell subsets seen in most inflammatory
Table II. Monoclonal Antibodies
CD MoAb Dilution Recognition Site (target cells) Sourcea
CD1a OKT6 1:80 LC, thymocytes Ortho
CD3 anti-Leu4 1:800 T3-complex BD
CD4 anti-Leu3a 1:100 T helper/inducer subset;
monocytes
BD
CD8 anti-Leu2a 1:100 T suppressor/cytotoxic subset BD
CD19 B4 1:200 pan B-cell marker Coulter
n.c. HLA-DR 1:600 HLA-DR ab complex BD
n.c. anti-Leu10 1:400 HLA-DQ ab complex BD
n.c. WT-31 1:40 ab TcR, framework determinant TCS
n.c. TCR-g/d 1:10 gd TcR, framework
determinant (g)
TCS
n.c. bF1 1:30 b chain of the TcR TCS
n.c. TCRdl 1:100 d chain of the TcR TCS
n.c. dTCS1 1:10 Vd1 TCS
n.c. BB3 1:300 Vd2 (A. Moretta, Genova)
n.c. TigA 1:1000 Vg2 (T. Hercend, Villejuif)
aBD, Becton Dickinson; TCS, T Cell Sciences.
Figure 1. For OKT6, a) distribution of LC within epidermis and upper portion
of the dermis in CCLE lesions and b) lack of LC within a perivascular infiltrate
underlying a CCLE lesion. Magnification  40.
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disease states. Intraepidermal CD3þ T cells displayed the CD8 molecule
in addition rather than the CD4 molecule, whereas the dermal infiltrating
CD3 þ cells were predominantly CD4 reactive. Essentially the same
distribution of T-cell subpopulations was seen in SCLE and ACLE lesions,
although the numbers of the inflammatory cells were considerably lower.
TcR Equipment: The staining pattern achieved with bF1 paralleled that
obtained with anti-Leu4 (although staining intensity with bF1 was clearly
less). In all biopsies the majority of CD3þ T cells was equipped with the
ab TcR, as evidenced with bF1 (Fig 3a,b). gd TcRþ T cells (Figs 4a,b)
represented between 0.5 and 15% of CD3 þ T cells compared to less
than 5% consistently observed in normal human skin [14] and non-
autoimmune skin disorders [30]. It is interesting to note that in seven of
eight biopsies performed while the CCLE patients were under a standard
treatment with hydroxychloroquine gd TcR þ T cells comprised
consistently more than 5% of the CD3þ T cells.
The distribution of BB3þ and TigAþ T cells compared to those of
A13 þ T cells was investigated in six of 14 CCLE patients and in three
biopsies from the SCLE patient. Except in one CCLE patient the majority
of the intralesional TcRd1 þ T cells (Fig 5) was clearly BB3þ (Fig 6)
Figure 2. For anti-Leu 4, a) distribution and accumulation of T cells within
epidermis and upper portion of the dermis in CCLE lesions and b)
accumulation of T cells within a perivascular infiltrate underlying a CCLE
lesion, from serial sections. Magnification: a,  20; b,  40.
Figure 3. For bF1, a) distribution and accumulation of T cells within
epidermis and upper portion of the dermis in CCLE lesions and b) accu-
mulation of T cells within a perivascular infiltrate underlying a CCLE lesion,
from serial sections. Magnification: a, 20; b, 40.
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and/or Tigaþ , and only single scattered cells displayed reactivity
with the MoAb A13. Therefore, the predominating intralesional gd TcR
þ T cells are Vg2/Vd2 þ , and thus correlate with the predominating gd
TcR phenotype found among circulating gd TcR þ T cells [23].
In ACLE lesions CD3þ T cells were sparse, and gd TcRþ cells were
rarely detectable. No further subtyping was therefore performed.
FACS Analysis of PBLs Thirty-two blood samples from patients with CCLE
were analyzed for CD3 þ T cells and their TcR equipment, respectively,
as shown in Table I. In general, gd TcR þ T cells comprised less than 5%
of CD3 þ T cells in the peripheral blood of CCLE patients, independent
of whether the patients were under hydroxychloroquine treatment or not.
However, one exception was observed in patient 12, who had 15.1%
CD3þ /gd TcR þ T cells (Fig 7a). Again, these peripheral gd T cells were
of the Vg2/Vd2 phenotype (Fig 7b).
DISCUSSION
LE in its various clinical forms, manifestations, and courses represents
a spectrum rather than a single distinct disease entity. The clinical,
histo- and immunopathologic, and serologic findings have been
thoroughly described [31–34], but the (common?) etiopatho-genetic
denominator still remains obscure. Twin and family studies have shown
that genetic factors play a significant role for systemic, sometimes life-
threatening LE [35], but it was not until recently that an association with
allotypic variants of HLA antigens also pointed to an immunogenetic
background in CCLE [18]. A significant increase was found for HLA-B7,
B8, Cw7, DR2, DR3, and HLA-DQwl [18] in a large number of patients.
We have investigated a smaller group of 26 CCLE patients (Fischer et al,
submitted). By RFLP analysis we found that the HLA-DRB*1601 and the
HLA-DQA*0102 alleles are significantly associated with CCLE [23%
frequency and relative risk (RR) 6.07 for HLA-DRB*1602 and 73% and
Figure 4. For TCRd1, a) distribution and accumulation of T cells within
epidermis and upper portion of the dermis in CCLE lesions and b)
accumulation of T cells within a perivascular infiltrate underlying a CCLE
lesion, from serial sections. Magnification: a,  20; b,  40.
Figure 5. Identification of intralesional gd TcRþ T cells: TCRd1.
Magnification  40.
Figure 6. Identification of intralesional gd TcR þ T cells: BB3. Magnification
of  40.
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4.23 for HLA-DQA*0102, respectively; pcorro0.01 for HLA-DRB*1602
and pcorro0.05 for HLA-DQA*0102]. The detailed results of this study
are to be published separately (Fischer et al, submitted). However, the
overrepresentation of these two allelic determinants is the strongest
genetic marker for CCLE yet found. Because family or twin studies
(except description of families with chronic granulomatous disease and
CCLE-like lesions) have so far not been performed, no definitive
conclusion regarding heritability can as yet be drawn from the etiologic
Figure 7. FACS analysis, a) Distribution of T-cell subsets among PBL in patient 12. b) Distribution of td TcR subsets among PBL in patient 12.
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fraction for CCLE patients. Because we have found a strong association
with the HLA-DQA*0102 allele, one may conclude that at least some of
the genetic predisposition for CCLE seems to be linked to the HLA-DQ
locus of the MHC. In particular, strong associations for HLA-DQ alleles
have been determined in various disorders with an autoimmune
pathogenesis, e.g., celiac disease [36], insulin-dependent diabetes
mellitus [37], pemphigus vulgaris [38], and allergic contact dermatitis
to nickel [39], and, most recently, a strong gene interaction between
HLA-DQ1 and HLA-DQ2 alleles leading to gene complementation has
been shown in LE-patients with anti-Ro/SSA autoantibody response [40].
It has been suggested that the pathogenic events operative in CCLE
represent a form of delayed-type hypersensitivity (DTH) reaction.
Therefore, it is particularly interesting to note a significant association
between a distinct HLA-DQA allele and another type IV immune
reaction, i.e., allergic contact dermatitis to nickel [39]. Whereas the
antigen in the latter reaction is well known, the nature of the antigen
remains an enigma in CCLE. Upgrading reactions in leprosy as well as
lepromin reactions are also cell-mediated DTH immune responses. The
presence of gd T cells in cutaneous lesions, which seem to be based on
alteration(s) in cell-mediated immunity, may be related to subtle changes
in type IV immune-reactivity, triggered by anti-inflammatory treatment
and/or by a putative infectious stimulus. In leprosy, gd TcRþ T cells
recognize highly conserved epitopes of mycobacteria of certain
molecular weight(s), e.g., 65-kD [41]. Certain epitopes of mycobacteria
as well as ‘‘stress proteins’’ are highly homologous, the latter representing
also highly conserved molecules throughout ontogeny and occurring in
response to stress reactions, e.g., heat or cold treatment, chemical agents,
etc. LE is a photosensitive condition and we therefore postulate that UV
radiation, by causing damage of epidermal cells, evokes either the
overproduction of stress proteins or the unmasking of epitopes that mimic
structural components that are homologous to mycobacterial proteins.
By using MoAbs recognizing variable determinants of the g and d TcR
chains the predominating phenotype of the gd TcRþ T cells, i.e., Vg2/
Vd2, corresponds to the phenotype found primarily on T cells in
peripheral blood and in lymphoepithelial organs, e.g., the tonsil [24].
Because this phenotype is not – or only to a small extent – found in the
thymus (or the spleen) the possibility arises that T cells equipped with the
gd TcR may be recruited from peripheral blood into the skin lesions,
where they proliferate and expand extrathymically in situ in response to
stimuli, which still remain to be identified. The possibility that the gd
TcRþ T cells proliferate already in the peripheral blood appears unlikely
based on the FACS data obtained. However, the stimuli leading to
proliferation of gdT cells as well as a putative restriction element for the
presentation of these agent(s) remain to be identified. Moreover, it
remains to be clarified whether the HLA-DRB*1602 and HLA-
DQA*0102 alleles contribute directly to the presentation of the as yet
unknown antigen to the gd TcRþ T cells.
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